Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 7Unknown 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Gastrointestinal Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Erythropoietin × Clear all
NCT00254436 2018-10-25

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Rectal Neoplasms

NCT01222195 2012-08-07

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2 Terminated
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡